Clinical Report: FDA approves once-weekly insulin for type 2 diabetes
Overview
The FDA has approved insulin efsitora alfa-gobe (Onswik), a once-weekly basal insulin for adults with type 2 diabetes. This approval is based on the QWINT phase 3 clinical trials, demonstrating noninferiority in glycemic control compared to daily insulin options.
Background
The management of type 2 diabetes often requires insulin therapy to achieve glycemic control. Understanding the efficacy and safety of these new treatments is essential for healthcare providers.
Data Highlights
| Trial | Participants | Comparison | Duration | Primary Endpoint |
|---|---|---|---|---|
| QWINT-1 | 795 | Insulin efsitora vs. insulin glargine | 52 weeks | Noninferiority for HbA1c reduction |
| QWINT-2 | 928 | Insulin efsitora vs. insulin degludec | 52 weeks | Noninferiority for HbA1c reduction |
| QWINT-3 | 986 | Insulin efsitora vs. insulin degludec | Duration not specified | Noninferiority for HbA1c reduction |
| QWINT-4 | 730 | Insulin efsitora vs. insulin glargine | Duration not specified | Noninferiority for HbA1c reduction |
Key Findings
- Insulin efsitora alfa-gobe is approved as a once-weekly basal insulin for type 2 diabetes.
- The QWINT phase 3 trials enrolled over 3,400 adults and demonstrated noninferiority in HbA1c reduction compared to daily insulins.
- Common adverse reactions include hypoglycemia, allergic reactions, and injection-site reactions.
- Insulin efsitora should not be used in patients with type 1 diabetes due to severe hypoglycemia risk.
- Concomitant use with thiazolidinediones may worsen heart failure.
Clinical Implications
Monitoring for common adverse reactions and contraindications is essential for safe use.
Conclusion
Insulin efsitora alfa-gobe has been approved for use in adults with type 2 diabetes.
Related Resources & Content
- Eli Lilly and Company, U.S. Food and Drug Administration, 2026 -- FDA approves Lilly's Onswik™ (insulin efsitora alfa-gobe)
- MDSpire News, 2026 -- FDA Approval Advances Basal Insulin
- MDSpire News, 2026 -- Once-Weekly Insulin Effective and Safe Alternative to Daily Dosing
- MDSpire News — FDA Panel Votes Against Weekly Insulin for T1D
- MDSpire News — Comparing Once-Weekly vs. Daily Insulin Administration for T2D
- Onswik™ (insulin efsitora alfa-gobe) for HCPs | Long-Acting Insulin
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026
- AACE Consensus Statement: Algorithm for Management of Adults with Type 2 Diabetes – 2026 Update
- U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes | Eli Lilly and Company
- U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes | Eli Lilly and Company
- News Details
- Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy - PubMed
- Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment - PubMed
- Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial - PubMed
- Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial - PubMed
- Efficacy and safety of once‐weekly insulins in type 2 diabetes: A systematic review and meta‐analysis - Bourron - 2026 - Diabetes, Obesity and Metabolism - Wiley Online Library
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
